Recurrent Near-Syncope with Symptomatic AV Block: Monitoring and Disposition

Bottom line up front

This patient has almost certainly crossed the threshold for admission to a telemetry-monitored bed today, not for another discharge-with-monitoring plan. The question of "what monitoring to arrange before discharge" presumes discharge is appropriate — on today's data, it very likely is not. He has ECG-documented second-degree AV block, a resting rate of 52 on a beta-blocker, three ED visits in a month for presyncope, and — critically — two witnessed episodes of abrupt pallor and unresponsiveness lasting ~30 seconds with spontaneous recovery. That description is a classic Stokes–Adams attack (transient ventricular standstill from intermittent high-grade AV block) until proven otherwise. The outpatient pathway has also demonstrably failed him (Holter denied twice, 6-week cardiology wait), and inability to secure timely outpatient evaluation is itself a legitimate disposition factor.

1. Reading the ECG correctly — and not being falsely reassured

"Sinus bradycardia with occasional dropped beats and a PR that varies between 180 and 240 ms" is second-degree AV block, most consistent with Mobitz type I (Wenckebach) on the surface tracing (progressive PR prolongation before the dropped beat). Three caveats keep this from being reassuring:

1. The surface rhythm between events does not explain the events. Thirty seconds of pallor and inability to speak implies cerebral hypoperfusion far beyond what an occasional single dropped beat produces. The daytime Wenckebach is likely the visible marker of a diseased conduction system that intermittently produces high-grade or complete block with a slow or absent escape. Wenckebach on the strip and paroxysmal infranodal block in real life can coexist, particularly in a 68-year-old with presumed degenerative conduction disease (Lev–Lenègre).
2. Verify Mobitz I vs. Mobitz II carefully on a long rhythm strip: constant PR before and after the dropped beat = Mobitz II, which is a major high-risk feature and an anticipated pacing indication regardless of symptoms. Also check QRS width and axis — a wide QRS with dropped beats points to infranodal disease even if the PR pattern looks Wenckebach-like. 2:1 block, if present anywhere on the strip, cannot be typed from the surface ECG at all.
3. Symptom–rhythm correlation is the diagnostic gold standard for syncope, and he is partway there already: recurrent presyncope + documented conduction disease is far stronger than either alone. Per the 2018 ACC/AHA/HRS bradycardia guideline, permanent pacing is a Class I recommendation for symptomatic second-degree AV block regardless of type or site of block, and for Mobitz II / high-grade / third-degree block regardless of symptoms when not due to reversible causes.

2. Differential diagnosis (ranked)

• Intermittent high-grade AV block / paroxysmal AV block (Stokes–Adams) — leading diagnosis given the witnessed episodes, documented second-degree block, and age.
• Beta-blocker–exacerbated conduction disease. Metoprolol 50 mg BID is a contributor, but treat it as an unmasker, not an innocent bystander: roughly half of patients with AV block attributed to AV-nodal agents have block that persists or recurs after drug withdrawal. Do not label this "reversible" and walk away — that is the classic error that produces the fourth ED visit as a cardiac arrest.
• Sinus node dysfunction / tachy–brady syndrome — sinus bradycardia at 52 on metoprolol is nonspecific, but SND and AV nodal disease frequently travel together ("binodal disease"); pauses may be sinus arrest rather than AV block.
• Vagally mediated (functional) AV block — favored only if episodes cluster with nausea, micturition, meals, or prodrome; the abrupt, prodrome-free description argues against it.
• Structural/infiltrative disease — get a TTE; in a 68-year-old with conduction disease consider cardiac amyloidosis (low-voltage discordance, wall thickness) and sarcoidosis; Lyme carditis if exposure history. Ischemia is less likely with three sets of negative troponins but a stress/ischemia evaluation may follow.
• Excluded or unlikely on current data: electrolyte derangement (K 4.2, Mg 2.0), hypothyroidism (TSH 2.4), anemia (Hgb 13.8), PE/hypoxia (SpO2 98%, normal RR). Also screen the med list for hidden AV-nodal offenders (diltiazem, digoxin, donepezil, ophthalmic beta-blockers) and ask about sleep apnea (nocturnal bradyarrhythmias).

Note the semantics: the daughter is describing true transient loss of consciousness / syncope, not "near-syncope." Reclassify it as such in the chart — it changes every downstream risk calculation.

3. Risk stratification — every scheme lands high

• 2018 ESC syncope guidelines (ED risk features): Mobitz II second-degree AV block is a major high-risk ECG feature; Mobitz I is a minor high-risk feature — but a minor feature combined with syncope consistent with an arrhythmic mechanism (abrupt, supine/exertional, no prodrome) escalates to high risk. Recurrent episodes, age 68, and bradycardia on the presenting ECG compound this. High-risk patients warrant prompt intensive evaluation in a monitored setting rather than discharge.
• 2017 ACC/AHA/HRS syncope guideline: suspected arrhythmic syncope with an abnormal ECG → hospital-based evaluation and continuous ECG monitoring (Class I for serious underlying causes).
• Canadian Syncope Risk Score: he scores at minimum in the medium-risk band (no vasovagal predisposition, plus an ED diagnosis of cardiac syncope; add points if QRS is wide or QTc >480 ms), i.e., a 30-day serious adverse event risk well above the ~1% discharge-comfortable range. But scores are decision supports: an ECG-documented conduction abnormality that plausibly explains the syncope is essentially a positive workup, not a risk estimate.
• San Francisco Syncope Rule: positive by "abnormal ECG" alone.

There is no mainstream risk framework in which this man is low risk.

4. Recommended disposition and inpatient pathway

Admit to a telemetry/monitored unit with cardiology (ideally EP) consultation. The inpatient sequence:

1. Continuous telemetry 24–48 h with event marking; instruct staff and family to flag any pallor/speech-arrest episode immediately so it can be matched to the rhythm strip. A single correlated pause or high-grade block episode is diagnostic and ends the workup.
2. Hold metoprolol (safe to stop abruptly in a monitored setting at this dose; the "taper" concern is about unmonitored outpatients with ischemic heart disease). Observe whether the block and bradycardia resolve. His hypertension can be covered with amlodipine or an ARB — there is no compelling indication tying him to a beta-blocker.
3. Localize the level of block if it persists: atropine or exercise (walk test) — improvement of conduction with increased sympathetic tone suggests AV-nodal (benign-ish) block; worsening suggests infranodal disease and mandates pacing. EP study is reserved for ambiguous cases.
4. TTE for structural disease; targeted labs only as suggested above (Lyme serology if exposure; amyloid workup if echo is suggestive).
5. Pacemaker decision:
   • Block persists off metoprolol + symptoms correlate, or any Mobitz II/high-grade/complete block is captured → permanent pacemaker before discharge (Class I).
   • Block resolves off metoprolol → still not "case closed." Given ~50% recurrence after withdrawal of the offending agent, he needs documented symptom resolution plus ambulatory monitoring after discharge; and per the 2018 guideline it is reasonable to pace without stopping a medically necessary drug — moot here since alternatives exist, but relevant if he later needs rate control for another indication.
6. Discharge planning that fixes the system failure: he leaves with a monitor on his chest (see below), a cardiology/EP appointment made by the inpatient team (admission converts the 6-week "new patient" wait into a hospital-follow-up slot), and the Holter insurance appeal rendered irrelevant.

5. If discharge is nonetheless pursued (patient declines admission, or telemetry is fully reassuring off metoprolol)

Then the monitoring strategy must satisfy three constraints: his event frequency (~weekly → a 24–48 h Holter is the wrong tool and was arguably wrong when ordered), the possibility of a life-threatening rhythm (needs real-time notification, not retrospective download), and the demonstrated insurance friction (needs to be dispensed now, from the ED).

• First choice: mobile cardiac outpatient telemetry (MCT) or a real-time–transmitting continuous patch monitor for 14–30 days, applied before he leaves the department. Real-time capability matters: an asymptomatic 8-second pause at 3 a.m. should trigger a phone call, not be discovered at day 30.
• Documentation to defeat the payer: code the encounter as second-degree AV block (I44.1) and syncope (R55) with explicit language — "ECG-documented second-degree AV block with recurrent witnessed transient loss of consciousness; monitoring required to establish symptom–rhythm correlation and pacemaker indication." Denials of Holters ordered for vague "near-syncope/fatigue" are common; denials of MCT for documented AV block with syncope are rare and appealable urgently by a physician peer-to-peer, which the ED or inpatient team should initiate before discharge rather than leaving the family to fight it.
• If 30 days of monitoring is nondiagnostic and episodes continue: implantable loop recorder (Class I in recurrent unexplained syncope; ESC gives ILR a strong recommendation early in suspected arrhythmic syncope when episodes are infrequent).
• Medication change regardless: stop metoprolol, substitute a non–AV-nodal antihypertensive, and recheck ECG and symptoms within 72 h–1 week.
• Expedited, not routine, cardiology: a 6-week wait is inappropriate for this presentation. Call the on-call cardiologist/EP from the ED; most systems have an urgent arrhythmia or syncope-unit pathway for exactly this scenario. Target review within 72 h–1 week.
• Safety-netting: no driving until the diagnosis is secured and treated (jurisdiction-specific, but syncope with probable arrhythmic cause carries a driving restriction essentially everywhere); teach the daughter to call EMS for any episode, and to note the time and check for a pulse if trained; return immediately for syncope, injury, exertional symptoms, or chest pain.

6. Explicit thresholds: admit vs. expedited outpatient

Admit (monitored bed) — any one of:

• ECG capture of Mobitz II, 2:1 with wide QRS, high-grade, or complete heart block
• Any true syncope (transient LOC) with the current ECG — which, per the daughter's history, he has already had
• Sinus pauses >3 seconds while awake, or symptomatic pauses of any length
• Symptomatic bradycardia (presyncope, pallor, confusion coincident with HR ≤50 or dropped beats)
• Syncope with injury, while supine, or during exertion
• New bundle branch block, QTc >480–500 ms, or ventricular ectopy/NSVT on the ED strip
• Structural heart disease, heart failure, or elevated troponin (absent here)
• Failure of the outpatient pathway: no monitor obtainable at discharge, or no cardiology contact achievable within ~72 h — the situation he is actually in

Expedited outpatient (monitor on chest at discharge + cardiology within 72 h–1 week) — only if all of:

• Isolated asymptomatic Mobitz I, especially nocturnal or with clear vagal context, narrow QRS
• No true syncope; symptoms plausibly explained by the beta-blocker, which has been stopped with a substitution plan
• Low/very-low-risk stratification (e.g., CSRS <1) — not achievable for him today
• Real-time ambulatory monitoring physically dispensed, follow-up appointment made (not "instructed to arrange"), reliable adult at home, driving restriction understood

He fails the outpatient criteria on multiple counts. The correct move is admission, metoprolol withdrawal under telemetry, EP evaluation, and a low threshold for permanent pacing — with the expectation that this is a pacemaker admission dressed up as a monitoring question.

Sources:

• 2018 ACC/AHA/HRS Guideline on Bradycardia and Cardiac Conduction Delay — ACC Ten Points
• 2018 ACC/AHA/HRS Bradycardia Guideline — Circulation (full text)
• 2018 ESC Guidelines for the Diagnosis and Management of Syncope
• Syncope Guidelines overview (2017 ACC/AHA/HRS, 2018 ESC, 2024 EuSEM) — Medscape
• Canadian Cardiovascular Society Clinical Practice Update on Syncope — CJC
• Canadian Syncope Risk Score impact on ED hospitalizations — PMC

Bottom Line

He should not leave with only “cardiology follow-up” pending. Given recurrent near-syncope, age >65, bradycardia with dropped beats, and delayed/denied outpatient monitoring, the safest plan is ED observation or admission on telemetry now, hold or reduce the metoprolol, and arrange ambulatory rhythm monitoring before any discharge.

If he remains stable after observation and no high-grade block or dangerous pauses are seen, he should leave with a monitor already applied: preferably 30-day mobile cardiac outpatient telemetry or an auto-trigger external loop recorder, not a 24- to 48-hour Holter. His episodes are intermittent over weeks, so short Holter monitoring has lower yield. A 14-day patch monitor is acceptable if that is the fastest available device, but real-time telemetry is preferable because it can alert for pauses, high-grade AV block, and severe bradycardia. Prolonged ECG monitoring is recommended when syncope remains unexplained and cardiac syncope is suspected; monitor choice should match symptom frequency. Holter is best for daily symptoms, patch for weekly symptoms, event/mobile telemetry for weekly-to-monthly symptoms, and implantable loop recorder for infrequent or recurrent unexplained severe events (AAFP 2023, Merck Syncope).

Why This Is Higher Risk

The ECG description sounds most consistent with Mobitz I/Wenckebach if the PR interval progressively lengthens before a dropped beat. However, the distinction matters: Mobitz II, high-grade AV block, and third-degree AV block are pathologic and usually require pacing unless a reversible cause is found (Merck AV Block). Beta-blockers can cause or worsen AV block, but medication effect should not be assumed to be the whole explanation in a 68-year-old with recurrent events.

Admit / Observe on Telemetry If Any of These Are Present

Admission or monitored ED observation is warranted for:

• Mobitz II, 2:1 AV block that cannot be localized, high-grade AV block, third-degree AV block, alternating bundle branch block, or new bifascicular block.
• Syncope/near-syncope with documented bradycardia, AV block, or pauses, especially if symptoms correlate with rhythm change.
• Persistent awake HR <40 bpm, symptomatic HR <50 bpm, or bradycardia with hypotension, altered mental status, chest pain, dyspnea, heart failure, or ischemic ECG changes.
• Sinus pause/asystole >3 seconds with symptoms, recurrent significant pauses, or prolonged asymptomatic pauses.
• Syncope during exertion, while supine, without prodrome, with injury, or with sudden palpitations.
• SBP <90 mmHg or >180 mmHg, hypoxia, elevated troponin, significant anemia, major electrolyte abnormality, acute heart failure, suspected PE, or persistent neurologic deficit.
• Inability to obtain same-day monitor placement or reliable rapid follow-up.

AAFP’s syncope review lists higher-risk features including persistent bradycardia, sinus pauses, Mobitz II/third-degree AV block, hypotension, older age, abnormal ECG, and suspected cardiac syncope; patients with high-risk cardiac features should be admitted or observed (AAFP 2023).

Expedited Outpatient Evaluation Is Reasonable Only If

Discharge can be considered only if all are true:

• No high-grade AV block, Mobitz II, complete heart block, dangerous pause, ischemia, or unstable vitals during ED/observation monitoring.
• ECG is clearly low-risk, e.g. narrow-complex Mobitz I or first-degree AV block, and symptoms improve after holding/reducing metoprolol.
• No ongoing chest pain, dyspnea, heart failure, GI bleed, electrolyte abnormality, or focal neurologic deficit.
• A rhythm monitor is applied before discharge, with automatic bradycardia/pause/AV-block detection and a named clinician/service receiving alerts.
• Cardiology/electrophysiology follow-up is expedited within days to 1-2 weeks, not six weeks.
• Clear return precautions and no driving until the cause is identified and treated.

For this specific patient, routine outpatient follow-up alone is inadequate. At minimum: telemetry observation, stop/reduce metoprolol, cardiology/EP phone consultation, and discharge only with a live 14- to 30-day ambulatory monitor already in place.

Monitoring strategy before discharge: Arrange prompt ambulatory ECG monitoring (e.g., 24–48-hour Holter if feasible, or preferably an external event/loop recorder, mobile cardiac outpatient telemetry [MCOT], or patch-based monitor like Zio) coordinated through the ED, cardiology, or electrophysiology service, with instructions for the patient or family on symptom-triggered recording and daily transmission if applicable. Pursue insurance appeal or alternative coverage for the previously ordered Holter; many payers cover extended external monitors or MCOT when Holter is nondiagnostic or symptoms are infrequent. Hold or reduce the metoprolol dose (e.g., to 25 mg twice daily or discontinue temporarily with blood pressure monitoring) pending results, as beta-blockers commonly contribute to sinus bradycardia, variable PR prolongation (180–240 ms consistent with first-degree or Mobitz I–type behavior), and dropped beats. Arrange expedited cardiology/EP follow-up within 1–2 weeks (bypassing the standard 6-week wait via ED referral, direct admit clinic, or telehealth bridge), with home instructions to return immediately for recurrent near-syncope, pallor episodes, HR <50 bpm with symptoms, chest pain, or syncope.[1]

Clinical thresholds for admission vs. expedited outpatient evaluation: Use risk stratification from the 2017 ACC/AHA/HRS syncope guideline. Admit for inpatient telemetry/monitoring (Class I recommendation for high-risk features) if there is suspicion of arrhythmic syncope with symptomatic bradycardia (<50 bpm), second-degree or higher AV block (Mobitz II, high-grade, or third-degree—here, occasional dropped beats and variable PR raise concern for conduction disease, potentially drug-induced Mobitz I), hemodynamic instability, recurrent presyncope with injury risk or during high-risk activities (driving, etc.), inability to arrange reliable outpatient monitoring within 24–48 hours, living alone or high fall risk, or comorbidities precluding safe discharge. Observation unit (12–24 hours) may suffice for intermediate-risk cases to complete short-term telemetry and initiate monitoring.[2]

Expedited outpatient evaluation is appropriate for lower-risk, stable patients (normal troponins, unremarkable CXR/labs, BP 118/76, O2 sat 98%, no acute ischemia) with suspected mild drug-related bradyarrhythmia or infrequent events, provided reliable monitoring is arranged before discharge, close family support exists, and clear return precautions are given. Recurrent near-syncope (three ED visits) and reported home episodes still tilt toward admission or observation in most cases due to age (68), ECG abnormalities, and beta-blocker use. Cardiology/EP input is ideal before final disposition.[3]

This approach aligns with guidelines emphasizing ECG-based risk assessment, frequency-tailored monitoring (Holter for frequent events; longer external or implantable for infrequent syncope), and hospital evaluation for serious conditions like symptomatic conduction disease while favoring outpatient pathways when safe.

Primary Disposition: Do Not Discharge

The premise of arranging an outpatient monitoring strategy prior to discharge is medically unsafe in this specific clinical context. This patient requires hospital admission for continuous inpatient telemetry.

According to the 2017 ACC/AHA/HRS Guidelines for the Evaluation and Management of Patients with Syncope, the presence of a serious medical condition—such as symptomatic second-degree atrioventricular (AV) block—is a Class I indication for hospital admission and evaluation.

Recommended Inpatient Monitoring and Management Strategy

The patient exhibits symptomatic bradycardia and second-degree AV block (indicated by dropped beats and varying PR intervals), exacerbated by an AV-nodal blocking agent (metoprolol). His daughter’s report of prolonged spells of extreme pallor and inability to speak is highly concerning for severe cerebral hypoperfusion, raising suspicion for intermittent high-grade block or prolonged ventricular pauses (Stokes-Adams attacks). Furthermore, the outpatient pathway has failed him due to insurance denials and unacceptable wait times.

The appropriate strategy includes:

1. Continuous Inpatient Telemetry: Admit to a monitored telemetry bed with transcutaneous pacing capability readily available. This allows for real-time symptom-rhythm correlation, which the delayed outpatient Holter pathway could not provide.
2. Medication Adjustment: Immediately discontinue metoprolol, which is likely inducing or worsening the underlying conduction disease. It should be replaced with a non-AV-nodal-blocking antihypertensive (e.g., a dihydropyridine calcium channel blocker, ACE inhibitor, or ARB).
3. Cardiology/Electrophysiology Consultation: An inpatient consultation definitively circumvents the 6-week outpatient wait and insurance barriers.
4. Structural Evaluation: Obtain a transthoracic echocardiogram to rule out underlying structural or infiltrative heart disease, as recommended for patients presenting with new conduction abnormalities and syncope.
5. Definitive Treatment: If telemetry demonstrates that the AV block resolves fully after the metoprolol washes out, it was likely drug-induced. If symptomatic AV block persists after the drug is cleared, the patient has intrinsic conduction system disease and meets a Class I indication for permanent pacemaker implantation prior to discharge.

Note on Outpatient Contingency: If the patient unequivocally refuses admission against medical advice (AMA), standard retrospective Holter monitoring is inadequate given the real-time risk. The only viable damage-mitigation alternative would be applying a Mobile Cardiac Telemetry (MCT) monitor in the ED, which alerts a live monitoring center to dangerous arrhythmias in real time. However, this is strictly a fallback; admission is the standard of care.

Clinical Thresholds: Admission vs. Expedited Outpatient Evaluation

Risk stratification per established syncope guidelines dictates disposition based on the following thresholds:

Thresholds for Hospital Admission (High-Risk Features present in this patient):

• Abnormal ECG: Evidence of significant conduction disease, including second-degree (Mobitz Type I or II) or third-degree AV block, severe bradycardia (<50 bpm), bifascicular block, or acute ischemia.
• High-Risk Symptoms: Near-syncope or syncope associated with documented or suspected pauses, occurring without a prodrome, while supine, during exertion, or associated with severe cerebral hypoperfusion (witnessed prolonged pallor and unresponsiveness).
• Systemic Outpatient Failure: Recurrent, unexplained high-risk episodes (three ED visits in one month) without prompt, accessible, and safe outpatient diagnostic capabilities.
• Patient History: Known structural heart disease, advanced age, or heart failure.

Thresholds for Expedited Outpatient Evaluation (Low-to-Intermediate Risk):

• Normal or Non-Diagnostic ECG: An entirely normal ECG without rhythm or conduction abnormalities.
• Clear Mechanism: Classic features pointing strictly toward benign reflex (vasovagal) syncope or orthostatic hypotension, with a clear precipitating event and rapid recovery.
• Absence of Underlying Disease: No history of structural heart disease or concerning family history (e.g., sudden cardiac death).
• Accessible Outpatient Follow-up: Reliable, rapid access to outpatient cardiology follow-up and diagnostic monitoring.

Monitoring Strategy and Disposition Thresholds for Recurrent Near-Syncope with Suspected Conduction Disease

Guideline-Based Principles

The 2018 ACC/AHA/HRS Bradycardia Guideline emphasizes that because symptomatic bradycardia and conduction disorders are often intermittent, prolonged ambulatory electrocardiographic monitoring is frequently required to establish temporal correlation between symptoms and rhythm disturbances. For daily symptoms, a 24- to 48-hour Holter is appropriate, but for less frequent symptoms, extended monitoring with external loop recorders, patch recorders, mobile cardiac outpatient telemetry (MCOT), or implantable cardiac monitors (ICMs) is indicated. External monitors are generally first-line, but for very infrequent symptoms, initial ICM implantation may be the most cost-effective strategy after a nondiagnostic initial workup ahajournals.org.

The 2017 ACC/AHA/HRS Syncope Guideline states that hospital-based evaluation is warranted to expedite treatment of identified serious conditions or to continue diagnostic evaluation when no presumptive cause is found. The presence of one or more serious medical conditions—specifically including symptomatic conduction system disease, Mobitz II or third-degree heart block, and symptomatic bradycardia or sinus pauses not related to neurally mediated syncope—is the key determinant for in-hospital management ahajournals.org.

Recommended Monitoring Strategy Before Discharge

Given this patient’s symptoms are occurring roughly every 1–2 weeks and a 24-hour Holter has already been denied and delayed, a short-duration Holter is unlikely to capture an event. The most appropriate monitoring strategy is:

1. Mobile cardiac outpatient telemetry (MCOT) for up to 30 days — This is the preferred option because it provides continuous, real-time monitoring with automatic transmission of significant arrhythmias to a central station attended 24 hours/day. It is specifically indicated for spontaneous symptoms that are too brief, too subtle, or too infrequent for patient-activated monitors and for high-risk patients whose rhythm requires real-time surveillance ahajournals.org.

2. External patch recorder (e.g., Zio XT) for 14 days — If MCOT is not available or insurance coverage is uncertain, a leadless, water-resistant patch recorder is a practical alternative. It is less cumbersome, improves compliance, and can record continuously for up to 14 days with patient-triggered symptom correlation ahajournals.org.

3. Implantable cardiac monitor (ICM) — If external monitoring is nondiagnostic or if symptoms prove to be very infrequent (e.g., monthly or less), an ICM should be considered as the next step. It is the most cost-effective initial strategy for recurrent, infrequent, unexplained symptoms after a nondiagnostic workup, with or without structural heart disease ahajournals.org.

Practical step: Before discharge, arrange either MCOT or a 14-day external patch recorder. If insurance barriers persist, consider direct referral for ICM implantation given the recurrent, concerning nature of the episodes and the failed outpatient Holter. Additionally, the metoprolol should be reviewed and potentially reduced or held, as it may be exacerbating bradycardia, but this should be coordinated with cardiology.

Clinical Thresholds Warranting Admission

Based on the 2017 Syncope Guideline’s Table 7 of serious medical conditions and the 2018 Bradycardia Guideline, admission for in-hospital telemetry and expedited workup is warranted if any of the following are present ahajournals.org ahajournals.org:

• Mobitz II second-degree AV block or third-degree (complete) heart block on ECG.
• Symptomatic bradycardia or sinus pauses >3 seconds that are not related to neurally mediated (reflex) syncope.
• Documented bradycardia temporally correlated with syncope or near-syncope (e.g., heart rate <40 bpm or pause >3 seconds during a symptomatic episode).
• Hemodynamic instability during the event (hypotension, altered mental status, or signs of shock).
• Recurrent Stokes-Adams attacks (sudden loss of consciousness without warning due to high-grade AV block or sinus arrest).
• Syncope in the setting of known structural heart disease or abnormal ECG suggesting significant conduction system disease.

In this patient, the ECG shows sinus bradycardia with occasional dropped beats and a variable PR interval (180–240 ms). If the dropped beats represent Mobitz II (sudden failure of conduction without preceding PR prolongation) or if there is any concern for high-grade or third-degree block, admission is indicated. Even if the pattern appears to be Mobitz I (Wenckebach), the recurrent near-syncope with possible Stokes-Adams episodes (“went pale and couldn’t talk”) and the failure of outpatient monitoring create a high-risk scenario that may justify admission for inpatient telemetry to characterize the rhythm and expedite pacemaker evaluation.

Clinical Thresholds for Expedited Outpatient Evaluation

Expedited outpatient evaluation (within 1–2 weeks, not the routine 6-week cardiology wait) is appropriate if the following conditions are met ahajournals.org ncbi.nlm.nih.gov:

• ECG shows only Mobitz I (Wenckebach) or first-degree AV block without evidence of Mobitz II or third-degree block.
• No documented sinus pauses >3 seconds and no hemodynamic compromise during episodes.
• Symptoms are presyncope or fatigue without frank syncope or Stokes-Adams attacks.
• No structural heart disease and no evidence of hemodynamic instability.
• Reversible causes are being addressed (e.g., reducing or holding metoprolol, correcting electrolytes if abnormal).
• A prolonged ambulatory monitor (MCOT or patch recorder) is in place before discharge to capture symptom-rhythm correlation.

Bottom Line for This Patient

This 68-year-old man has recurrent near-syncope with documented bradycardia and possible AV conduction disease, plus home episodes concerning for significant cerebral hypoperfusion. Because outpatient Holter has been denied and symptoms are intermittent, MCOT for 30 days (or a 14-day external patch recorder) should be arranged before discharge. If the ECG demonstrates Mobitz II or third-degree block, symptomatic pauses >3 seconds, or any bradycardia clearly correlated with syncope, he should be admitted for inpatient telemetry and expedited electrophysiology evaluation. If the conduction abnormality is limited to Mobitz I or first-degree block without high-grade pauses, he may be managed with expedited outpatient evaluation (within 1–2 weeks) provided a prolonged monitor is applied and metoprolol is reassessed. Given the recurrent, concerning episodes and the failed outpatient pathway, strong consideration should be given to admission for inpatient characterization of the rhythm and possible pacemaker evaluation.